AUS
NZ
UK
CA
USA
IND
Healthcare
CSL Faces a Defining Phase as Market Watches the Next Strategic Move
July 15, 2026 03:44 PM AEST| By SamExplore how CSL is navigating operational challenges, leadership changes and strategic priorities while maintaining its position among Australia's leading healthcare companies and major market indices.
CSL Faces a Defining Phase as Market Focus Shifts to Margins
July 15, 2026 02:54 PM AEST| By SamExplore how CSL's operational developments, margin outlook and strategic priorities are reshaping market expectations as investors monitor the healthcare leader's next phase of growth.
What Makes (ASX:RCE) a Healthcare Pipeline Signal?
July 15, 2026 02:30 PM AEST| By SamRecce remains in healthcare focus as anti-infective research, clinical milestones, patent protection, regulatory progress and disciplined funding shape the credibility of its developing biotechnology pipeline across Australia’s selective market.
Why Is NEU (ASX:NEU) Becoming Biotech’s Credibility Test?
July 15, 2026 02:28 PM AEST| By SamNeuren remains a biotechnology sentiment gauge as regulatory progress, royalty visibility, clinical evidence, market uptake, partner execution and disciplined funding shape its evolving healthcare narrative across Australia’s selective market.
Can Flight Centre (ASX:FLT) And These Founder-Led Stocks Handle Today's Market Uncertainty?
July 15, 2026 11:14 AM AEST| By SamFlight Centre, Macquarie Technology Group and Mesoblast remain on investor watchlists as founder-led Australian businesses operating across travel, technology and healthcare. Investors continue monitoring execution, growth initiatives and long-term b...
What Puts ResMed (ASX:RMD) At The Heart Of Healthcare Reset?
July 15, 2026 10:46 AM AEST| By SamResMed enters a healthcare reset as portfolio focus, sleep-device demand, margin discipline and capital choices shape how the market assesses its core respiratory technology business and commercial resilience today.
Can Cochlear (ASX:COH) Turn FDA Approval Into Its Next Growth Driver?
July 15, 2026 10:44 AM AEST| By SamCochlear has received FDA clearance for its rechargeable Osia 3 Sound Processor, strengthening its hearing implant portfolio and recurring upgrade strategy while expanding innovation across its bone conduction hearing ecosystem.
Why Is Little Green Pharma (ASX:LGP) Quoting Additional Shares on the ASX?
July 15, 2026 10:30 AM AEST| By SamLittle Green Pharma has applied to quote additional ordinary shares on the ASX following the exercise of existing securities. The routine capital management activity expands the company's listed share base while supporting ongoing compliance and trad...
Imaging Software Becomes ASX Healthcare's Bright Spot
July 14, 2026 10:30 PM AEST| By SamA renewed North American health network agreement has lifted Pro Medicus, while Telix extends the diagnostics theme. Contract-backed recurring revenue is proving valuable in an unsettled and nervous market.
Cochlear (ASX:COH) And ResMed (ASX:RMD) Stir As ASX Device Makers Find Form
July 14, 2026 10:28 PM AEST| By SamASX medical device makers have rebounded after a severe de-rating driven by macro forces rather than operations. Cochlear, ResMed and Ramsay each face distinct pressures ahead of August full-year results.
CSL (ASX:CSL) Leads A Healthcare Rebound Few Saw Coming
July 14, 2026 10:27 PM AEST| By SamASX healthcare has rebounded forcefully from multi-year lows, led by CSL and Sonic Healthcare, as capital rotates back into defensives. August full-year results will test whether earnings support the recovery.
Top Healthcare Stocks: Is ResMed (ASX:RMD) Sharpening Its Focus?
July 14, 2026 05:49 PM AEST| By SamResMed remains in focus as sleep-device demand, connected software, portfolio discipline, recurring patient activity and cash conversion shape confidence across Australia’s selective healthcare market and global respiratory care sector.
HeraMED Strengthens Digital Pregnancy Care Through US Pilot Success
July 14, 2026 04:52 PM AEST| By SamDiscover how HeraMED is advancing digital maternity care through a completed US healthcare pilot, highlighting remote pregnancy monitoring, improved clinical workflows, and the growing role of connected healthcare solutions.
Why Recce Pharmaceuticals (ASX:RCE) Is Expanding Its ASEAN Footprint
July 14, 2026 03:05 PM AEST| By SamRecce Pharmaceuticals expands its ASEAN strategy with a Vietnam patent, strengthening intellectual property protection while advancing clinical development, regional partnerships, and future commercial opportunities across Southeast Asia.
Why Is CSL Back in the Healthcare Repair Conversation?
July 14, 2026 11:49 AM AEST| By SamCSL returns to the healthcare repair debate as plasma recovery, margin discipline, cash conversion and balance-sheet strength provide a clearer test of operational quality across Australia’s selective share market.
Top Healthcare Stocks to Watch: Is Cochlear (ASX:COH) Facing a Demand Test?
July 14, 2026 11:49 AM AEST| By SamCochlear remains in focus as implant demand, hospital capacity, referral activity, cash conversion and disciplined execution shape confidence across Australia’s healthcare market and broader medtech sector today.
Why Are Telix Pharmaceuticals (ASX:TLX) and Other Insider-Owned Growth Stocks in Focus?
July 14, 2026 10:48 AM AEST| By SamTelix Pharmaceuticals, Predictive Discovery and Lindian Resources remain in focus as investors assess insider ownership, business expansion and long-term growth opportunities across healthcare and resource sectors.
Why ASX imaging names are leading healthcare today
July 13, 2026 10:24 PM AEST| By SamASX health technology names moved to the front of the healthcare conversation, with radiopharmaceutical and medical-imaging stories drawing attention as the sector steadied to open a cautious trading week.
Mesoblast (ASX:MSB) shares in focus as cell therapy revenue lands
July 13, 2026 10:12 PM AEST| By SamMesoblast has reported its first full year of commercial revenue for its approved cell therapy, lifting attention across ASX biotech names as the wider healthcare sector steadied to open the week.
Aroa Biosurgery (ASX:ARX) in focus as reimbursement clarity approaches
July 13, 2026 10:10 PM AEST| By SamAroa Biosurgery has come into focus as the market waits on clearer reimbursement rules for its regenerative wound-care products, with the second half of the financial year shaping as a key stretch for the ASX name.
Advertise your brand on Kalkine Media